# Kirk N. Campbell

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kirk-n-campbell/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,091 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 35 |
| i10-index | 61 |
| Last Known Institution | University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5072780668 |
| ORCID iD | 0000-0003-3855-8651 |
| Works | 135 |

## Researcher papers

- [The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A](https://scholariq.org/papers/the-actin-cytoskeleton-of-kidney-podocytes-is-a-direct-target-of-the/)
- [Abatacept in B7-1–Positive Proteinuric Kidney Disease](https://scholariq.org/papers/abatacept-in-b7-1-positive-proteinuric-kidney-disease/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants](https://scholariq.org/papers/inaxaplin-for-proteinuric-kidney-disease-in-persons-with-two-i-apol1-i-variants/)
- [Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids](https://scholariq.org/papers/regulation-of-podocyte-survival-and-endoplasmic-reticulum-stress-by-fatty-acids/)
- [DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS](https://scholariq.org/papers/duet-a-phase-2-study-evaluating-the-efficacy-and-safety-of-sparsentan-in/)
- [Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap](https://scholariq.org/papers/autophagy-is-a-gatekeeper-of-hepatic-differentiation-and-carcinogenesis-by/)
- [Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis](https://scholariq.org/papers/loss-of-decay-accelerating-factor-triggers-podocyte-injury-and/)
- [A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis](https://scholariq.org/papers/a-phase-2-double-blind-placebo-controlled-randomized-study-of-fresolimumab-in/)
- [Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment](https://scholariq.org/papers/mutations-in-six-nephrosis-genes-delineate-a-pathogenic-pathway-amenable-to/)
- [Focal Segmental Glomerulosclerosis](https://scholariq.org/papers/focal-segmental-glomerulosclerosis-2/)
- [Immunoglobulin A Nephropathy: New Treatment Options](https://scholariq.org/papers/immunoglobulin-a-nephropathy-new-treatment-options/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Researcher university

- [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.